华东医药股份有限公司 2025年第二次临时股东会决议公告

Meeting Information - The meeting was held on December 9, 2025, at 14:00 in Hangzhou, Zhejiang Province, at the new building of East China Pharmaceutical Co., Ltd. [3] - The meeting was conducted through a combination of on-site and online voting [4] Attendance - A total of 526 shareholders attended the meeting, representing 1,074,532,240 shares, which is 61.2611% of the total voting shares [5] - Among them, 524 minority shareholders participated, representing 55,594,083 shares, or 3.1695% of the total voting shares [6] Proposal Voting Results - The proposal to repurchase and cancel part of the restricted stock was approved with 1,074,435,740 shares in favor, accounting for 99.9910% of the valid votes [7] - Minority shareholders voted 55,497,583 shares in favor, representing 99.8264% of the valid votes [9] - The proposal to expand the business scope and amend the registered capital was also approved with 1,074,460,440 shares in favor, which is 99.9933% of the valid votes [10] - Minority shareholders voted 55,522,283 shares in favor, representing 99.8708% of the valid votes [11] Legal Opinion - The legal opinion from Zhejiang Tianche Law Firm confirmed that the meeting's procedures and voting were in compliance with relevant laws and regulations [12] Share Capital Changes - Following the repurchase, the total number of shares will decrease from 1,754,021,048 to 1,753,736,848 shares, and the registered capital will reduce from 1,754,021,048 yuan to 1,753,736,848 yuan [15]